Loading...
Prostate cancer patients who are obese generally have more-aggressive disease and higher risks for biochemical failure (rising prostate-specific antigen [PSA] levels) and disease-specific mortality than do patients with normal body weight (Cancer 2007; 110:2691). Of the many metabolic changes manifested in obese patients, hyperinsulinemia is considered a potential mediator of unfavorable outcomes. To assess the role of prediagnostic body-mass index (BMI) and plasma C-peptide concentrations (a marker of insulin secretion) in prostate cancer mortality, investigators used data from the Physicians’ Health Study, a randomized trial of aspirin and beta carotene in more than 20,000 U.S. male physicians without histories of cancer or major chronic …